{"nctId":"NCT01101451","briefTitle":"Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery","startDateStruct":{"date":"2010-04-12","type":"ACTUAL"},"conditions":["Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Cervical Squamous Cell Carcinoma, Not Otherwise Specified","Stage I Cervical Cancer AJCC v6 and v7","Stage IA Cervical Cancer AJCC v6 and v7","Stage IB Cervical Cancer AJCC v6 and v7","Stage IIA Cervical Cancer AJCC v7"],"count":340,"armGroups":[{"label":"Arm I (EBRT, IMRT)","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: External Beam Radiation Therapy","Radiation: Intensity-Modulated Radiation Therapy","Other: Laboratory Biomarker Analysis","Other: Quality-of-Life Assessment","Other: Questionnaire Administration"]},{"label":"Arm II (cisplatin, EBRT, IMRT)","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Radiation: External Beam Radiation Therapy","Radiation: Intensity-Modulated Radiation Therapy","Other: Laboratory Biomarker Analysis","Other: Quality-of-Life Assessment","Other: Questionnaire Administration"]}],"interventions":[{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone''s Chloride","Peyrone''s Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"]},{"name":"External Beam Radiation Therapy","otherNames":["Definitive Radiation Therapy","EBRT","External Beam Radiation","External Beam Radiotherapy","External Beam RT","external radiation","External Radiation Therapy","external-beam radiation","Radiation, External Beam"]},{"name":"Intensity-Modulated Radiation Therapy","otherNames":["IMRT","Intensity Modulated RT","Intensity-Modulated Radiotherapy","Radiation, Intensity-Modulated Radiotherapy"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"]},{"name":"Questionnaire Administration","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically proven primary cervical cancer I-IIA with squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma initially treated with a standard radical hysterectomy with pelvic lymphadenectomy\n* Patients with the following characteristics (depth of stromal invasion and lymphovascular space involvement to be pathologically confirmed):\n\n  * Positive capillary-lymphovascular space involvement and one of the following:\n\n    * Deep third penetration\n    * Middle third penetration, clinical tumor \\>= 2 cm\n    * Superficial third penetration, clinical tumor \\>= 5 cm\n  * Negative capillary-lymphatic space involvement\n\n    * Middle or deep third penetration, clinical tumor \\>= 4 cm\n* Absolute neutrophil count (ANC) \\>= 1,500/mcl\n* Platelets \\>= 100,000/mcl\n* Creatinine =\\< upper limit of normal (ULN) or calculated creatinine clearance \\>= 60 mL/min\n* Bilirubin =\\< 1.5 x normal\n* Alkaline phosphate =\\< 3 x normal\n* Serum glutamic oxaloacetic transaminase (SGOT) =\\< 3 x normal\n* Gynecologic Oncology Group (GOG) performance status 0, 1, 2\n* Patients should not be randomized less than 3 weeks post-surgery but will not be acceptable for randomization more than 8 weeks post-surgery\n* Patients who have met the pre-entry requirements\n* Patients must have signed an approved informed consent and authorization permitting release of personal health information\n\nExclusion Criteria:\n\n* Patients with tumor in the parametria, pelvic lymph nodes or any other extra uterine site or with positive surgical margins\n* Patients with septicemia or severe infection\n* Patients with intestinal obstruction or gastrointestinal bleeding\n* Patients with postoperative fistula\n* Patients with cervix cancer who have received any previous radiation or chemotherapy\n* Patients whose circumstances do not permit completion of the study or the required follow-up\n* Patients with renal abnormalities requiring modification of radiation field (pelvic kidney, renal transplant, etc.)\n* Patients with GOG performance status of 3 or 4\n* Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Recurrence-free Survival (RFS) Rate at 3-years","description":"Estimate for probability of RFS at 3 years using Kaplan-Meier method, where RFS is defined as time from protocol registration (and randomization) to the date of first documented recurrence, death, or the date of last contact, whichever occurs first. Patients without recurrence or death were censored at the date of last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null},{"groupId":"OG001","value":"88.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Rate at 3-years","description":"Estimate for probability of overall survival at 3 years by Kaplan-Meier method, where overall survival is defined as the time from randomization to time of death due to any cause or the date of last contact, whichever occurs first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.3","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period.","description":"Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Risk-benefit","description":"The reporting group (2) did not demonstrate improved RFS compared to the reporting group (1) at the pre-specified significance level. Per the protocol, patient risk-benefit will be assessed only for a positive study.\n\nThis is not assessed due to non-positive study per the protocol.","classes":[]},{"type":"SECONDARY","title":"Quality of Life (QOL) as Measured With the FACT-Cx TOI","description":"The patient-reported QOL is assessed with the Trial Outcome Index of the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx TOI). The FACT-Cx TOI is ranged 0-116 and a larger FACT-Cx TOI score suggests a favorable QoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":"15.4"},{"groupId":"OG001","value":"80.1","spread":"15.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.0","spread":"16.4"},{"groupId":"OG001","value":"71.4","spread":"15.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.1","spread":"17.0"},{"groupId":"OG001","value":"71.8","spread":"17.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":"15.5"},{"groupId":"OG001","value":"88.1","spread":"12.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Treatment Compliance","description":"Assessed by the number of cycles and amount of chemoradiotherapy administered, treatment span, incidence and duration of treatment delays, reason for delays, and reason why off study therapy.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Site(s) of Recurrence","description":"The site(s) of first disease recurrence will be classified as: pelvic-only, extra-pelvic-only or pelvic-and-extra-pelvic and tabulated by treatment group. The test of the hypothesis that the probability of local failure is independent of randomized treatment will be assessed with exact logistic regression adjusted know prognostic factors.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Local Control","description":"Assessed with Exact Logistic Regression adjusted known prognostic factors.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":170},"commonTop":["White Blood Cell Decreased","Nausea","Anemia","Diarrhea","Neutrophil Count Decreased"]}}}